Foresite capital fund reports passive stake in arbutus biopharma

Foresite capital fund iv, l.p. reports 5.6% passive stake in arbutus biopharma as of dec 2, 2019 - sec filing.
ABUS Ratings Summary
ABUS Quant Ranking